Patients with dMMR endometrial cancer may benefit from immunotherapy1

Endometrial cancer has the highest rate of mismatch repair deficiency (dMMR) across tumor types2,3

  • 25%-30% of endometrial cancer patients have dMMR tumors3,4

dMMR endometrial cancer tumors can be associated with:

Icon: Recurrence rate

a higher
recurrence rate5

Icon: Distant recurrences

a higher rate of distant
recurrences5

Icon: Lynch syndrome

Lynch syndrome, a germline mutation that increases the risk
of other cancers1

Tumors with dMMR are more likely to respond to anti–PD-1 therapies like JEMPERLI6

  • Increased mutations promote antitumor immune cell reaction and increased tumor-infiltrating lymphocytes

Test your endometrial cancer patients for dMMR1,6-8

Icon: Microscope

Determine MMR status using immunohistochemistry (IHC)

  • IHC is a reliable and accurate testing method to determine if a tumor is dMMR and identify patients who may benefit from immunotherapy6,7
  • There is an IHC-based, FDA-approved test that can confirm patient eligibility for JEMPERLI7,8
Icon: Thumbs up

For recurrent/advanced endometrial cancer, National Comprehensive Cancer Network (NCCN) recommends dMMR testing if not previously done

Testing for dMMR using IHC helps identify patients who may be appropriate for JEMPERLI

Icon: Lightbulb
  • See the mechanism of action (MOA) for JEMPERLI

    The dMMR tumor cell journey 

    dMMR upregulates PD-1/PD-L19

    JEMPERLI is a PD-1–blocking antibody7

    • JEMPERLI binds to PD-1 to block interactions between PD-1 and PD-L1 or PD-L2
    • This releases the PD-1 pathway-mediated inhibition of the anti-tumor immune response to kill cancer cells*

    Blockage of the PD-1 receptor can restore T cell function10,11

    Inhibited T Cell

    Inhibited T Cell10,11

    • Cancer cells can increase expression of PD-L1 on their surface, which binds to PD-1 on T cells
    • This reduces the immune system's ability to identify and attack the cancer cells

    Activated T Cell With JEMPERLI7,10,11

    • JEMPERLI binds to PD-1 receptors on the T cells, blocking PD-L1 or PD-L2 interactions
    • This enables the T cell to identify and attack cancer cells by restoring cytotoxic activity in the T cell

    dMMR=mismatch repair deficient; PD-1=progammed death receptor-1; PD-L1=programmed death ligand 1; PD-L2=programmed death ligand 2.

    *In mouse tumor models.7

    JEMPERLI harnesses the power of the immune system7

    Icon: Lightbulb

Recurrent/advanced endometrial cancer patients need effective and durable treatment options8,12,13

Most patients with recurrent or advanced endometrial cancer have a poor prognosis, with ORR dropping to <20% on 2L single-agent chemotherapy8,12†

Chart: ORR for 1L and 2L single-agent chemotherapy

ORR up to 27% has been reported in patients treated with paclitaxel who have been previously exposed to the treatment.14

1L=first-line; 2L=second-line.

2L chemotherapy in patients with recurrent or advanced endometrial cancer, historically, has shown a median duration of response of less than 1 year (4.2 to 11 months)14,15

Median Duration of response less than one year
  • There is no generally accepted standard of care within the oncology community for the treatment of recurrent or advanced endometrial cancers that have progressed on or after platinum-based therapy12,13
  • Only 3 therapies or combinations of therapies for endometrial cancer have been approved by the FDA since 201716,17
Icon: JEMPERLI (dostarlimab-gxly) Response Rate

Learn about response with
 JEMPERLI.

Icon: JEMPERLI (dostarlimab-gxly) Trial

Explore the pivotal trial
for JEMPERLI.

Icon: JEMPERLI (dostarlimab-gxly) Mechanism of Action

Learn how JEMPERLI
activates T cells.